Jun 28 2017 Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program View
Apr 13 2017 Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder View
Feb 15 2017 Relmada Therapeutics to Participate in the 2nd Annual Disruptive Growth & Healthcare Conference View
Jan 25 2017 Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone View
